SCHEMBL955682

SCHEMBL955682

O=C(O)c1sc(-c2ccnc3[nH]ccc23)nc1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 4/20 0.56
ROCK1 Q13464 3/20 0.56
IKBKB O14920 2/20 0.56
CHUK O15111 2/20 0.56
IGF1R P08069 2/20 0.56
JAK2 O60674 2/20 0.56
DAPK3 O43293 1/20 0.56
PRKD3 O94806 1/20 0.56
MAP4K4 O95819 1/20 0.56
PAK4 O96013 1/20 0.56
CSF1R P07333 1/20 0.56
RET P07949 1/20 0.56
FGFR1 P11362 1/20 0.56
PRKACA P17612 1/20 0.56
FLT1 P17948 1/20 0.56
LTK P29376 1/20 0.56
GRK5 P34947 1/20 0.56
KDR P35968 1/20 0.56
MAP2K2 P36507 1/20 0.56
MAPK8 P45983 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL953404 0.91 CDC7 (0.55) AURKBROCK1IKBKBCHUKIGF1R
SCHEMBL956033 0.76 JAK2 (0.51) AURKBROCK1IKBKBCHUKIGF1R
SCHEMBL974859 0.73 CDC7 (0.84) CDC7DBF4
SCHEMBL857275 0.73 IKBKB (1.00) AURKBROCK1IKBKBCHUKIGF1R
SCHEMBL16039727 0.73 KDM4E (0.68) CDC7DBF4
SCHEMBL952767 0.73 CDC7 (0.54) KDRCDC7DBF4
SCHEMBL1717982 0.73 NUDT1 (0.62) AURKBROCK1IKBKBCHUKIGF1R
SCHEMBL98272 0.72 ROCK1 (0.62) AURKBROCK1IKBKBCHUKIGF1R
Trifluoroacetic Acid SCHEMBL29540593 0.71 ROCK1 (0.58) AURKBROCK1IKBKBCHUKIGF1R
Trifluoroacetic Acid SCHEMBL99512 0.71 ROCK1 (0.58) AURKBROCK1IKBKBCHUKIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
CN-102395585-A Heteroaryls and their use as pi3k inhibitors MILLENNIUM PHARM INC 2012-03-28 CN disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 AURKB 516/4885ROCK1 816/4885IKBKB 419/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 AURKB 656/4885ROCK1 150/4885IKBKB 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.